CompletedNot Applicable

Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs

United States801 participantsStarted 2018-02-08

Plain-language summary

Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in uncomplicated and 19.9% in complicated. ESBL-producing Enterobacteriaceae were found in 7.7% of all cases, 2.6% in uncomplicated and 12.2% in complicated. More recently, Enterobactericeae and gram-negative non fermenting bacteria have started to show resistance to carbapenems (CREs and CR-NF). Patients hospitalized with UTI and urosepsis represent a higher risk population for infections due to multi-drug resistant bacteria and experience serious adverse outcomes, including death. EMERGEncy ID NET will conduct a study to determine the prevalence of ESBL-producing, CREs and CR-NFs among this high risk population of patients admitted for UTI from U.S. emergency departments.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age greater than or equal to 18 years;
✓. Admitted to the hospital through the ED;
✓. Primary reason for admission is treatment of UTI with or without sepsis (i.e., ED diagnosis of UTI and/or sepsis); and
✓. Provide verbal or written consent to participate in the study or if patient is unable to provide consent (e.g., altered mental status), consent obtained from a legal authorized representative.

Exclusion criteria

✕. they are unable to provide a urine specimen for culture; or
✕. their urine culture yields no growth or is contaminated (see definition of positive urine culture below). Note: If participant's urine culture is contaminated but their blood culture is positive for a uropathogen, they will not be excluded.

What they're measuring

Prevalence of ESBL-producing Enterobacteriaceae

Timeframe: 2 years

Prevalence of carbapenem-resistant Enterobacteriaceae (CRE)

Timeframe: 2 years

Prevalence of carbapenem-resistant non fermenting gram negative bacteria

Timeframe: 2 years

Trial details

NCT IDNCT03346603

SponsorOlive View-UCLA Education & Research Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-02-28

View on ClinicalTrials.gov More Urinary Tract Infections trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age greater than or equal to 18 years;
✓. Admitted to the hospital through the ED;
✓. Primary reason for admission is treatment of UTI with or without sepsis (i.e., ED diagnosis of UTI and/or sepsis); and
✓. Provide verbal or written consent to participate in the study or if patient is unable to provide consent (e.g., altered mental status), consent obtained from a legal authorized representative.

Exclusion criteria

✕. they are unable to provide a urine specimen for culture; or
✕. their urine culture yields no growth or is contaminated (see definition of positive urine culture below). Note: If participant's urine culture is contaminated but their blood culture is positive for a uropathogen, they will not be excluded.